Spoed!
Menu

PubMed publicaties

Sinds begin jaren 60 zijn er veel wetenschappelijke artikelen gepubliceerd over de schadelijke effecten van Softenon op de ongeboren vrucht en op de ouder wordende Softenon slachtoffers. Een verzameling van de meest recent gepubliceerde artikelen vindt u hieronder. De volledige lijst met titels en abstracts kunt u vinden, door hier te klikken.

4.7 Medische informatie_Pubmed publicaties.jpg

2017 Impact Thalidomide use Brazil. Er wordt met een kritische blik gekeken naar de geschiedenis van Thalidomide in Brazilie en naar het voorkomen van Thalidomide Embryopathie in de afgelopen decennia.

2015 Blood pressure in thalidomide-impaired patient. Een publicatie van anesthesie bij een Softenon slachtoffer zonder armen en met benen waarbij ovariumcystectomie wordt uitgevoerd.

Jan 2025 Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.
In CARTITUDE-4, ciltacabtagene autoleucel (cilta-cel) significantly improved progression-free survival (primary endpoint; previously reported) versus standard of care in patients with relapsed, lenalidomide-refractory...

Jan 2025 Phthalimides as anti-inflammatory agents.
Isoindoline-1,3-dione, also referred as phthalimide, has gained recognition as promising pharmacophore due to the documented biological activities of its derivatives. Phthalimides are a family of synthetic molecules t...

Dec 2024 PTGES3 proteolysis using the liposomal peptide-PROTAC approach.
Hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide, and the lack of effective biomarkers for early detection leads to poor therapeutic outcomes. Prostaglandin E Synthase 3 (PTGES3) ...

Dec 2024 A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well-Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's Disease.
This study aimed to investigate the efficacy and safety of a triple therapy consisting of colchicine, thalidomide and total glucosides of paeony (TGP) in Behcet's disease (BD) patients with mucocutaneous involvement.

2024 Prevalence of fungal colonization among patients with psoriasis in difficult-to-treat areas: impact of apremilast on mycotic burden and clinical outcomes.
Fungi, including , may be a trigger or exacerbate psoriasis, especially in difficult to treat (DTT) areas, through the activation of IL-17/23 axis.

2024 Polymorphisms within genes encoding Ikaros family proteins IKZF1 and IKZF3 in multiple myeloma patients treated with thalidomide.
Multiple myeloma (MM) is a hematological malignancy characterized by the presence of abnormal plasma cells. It is associated with anemia, bone lesions and renal dysfunction. Immunomodulatory drugs (IMiDs) are commonly...

2024 Serum IL-23 levels reflect a myeloid inflammatory signature and predict the response to apremilast in patients with psoriatic arthritis.
The phosphodiesterase 4 (PDE4) inhibitor apremilast downregulates the production of IL-23 and other pro-inflammatory cytokines involved in the pathogenesis of psoriatic arthritis (PsA).

Dec 2024 Comparing the efficacy of oral apremilast, intralesional corticosteroids, and their combination in patients with patchy alopecia areata: a randomized clinical controlled trial.
Alopecia areata (AA) is a chronic, immune-mediated inflammatory disorder characterized by nonscarring hair loss. The management of AA poses challenges due to its unpredictable course and variable response to treatment...

Dec 2024 Selective small molecule inhibitors for hidradenitis suppurativa: Today and tomorrow.
Hidradenitis suppurativa (HS) is an autoinflammatory condition characterized by abscesses, inflammatory nodules, and tunnels in intertriginous sites of the body. The pathogenesis of HS involves follicular occlusion in...

Nov 2024 BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.
B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR T-cell) therapy has exhibited remarkable efficacy in refractory or relapsed multiple myeloma (R/R MM), but recurrence and rapid progressi...

A A Vergroot
Print
Nesos ZonMw Ministerie van volksgezondheid, welzijn en sport ZonMw
Ministerie van volksgezondheid, welzijn en sport
ZonMw
ZonMw